低睾酮与正常睾酮男性中总PSA及游离PSA比值的诊断性能比较
该研究基于REDUCE试验安慰剂组3295例既往活检阴性后2年内接受前列腺活检的男性,比较低睾酮(<300 ng/dL)与正常睾酮男性中总PSA、游离PSA比值和PSA密度对前列腺癌及临床显著前列腺癌的诊断性能。结果显示两组间这些指标的敏感性、特异性和准确性相似。
要点
- 低睾酮男性中总PSA、游离PSA比值和PSA密度的诊断性能与正常睾酮男性相当。
- 低睾酮组前列腺癌和临床显著前列腺癌的患病率分别为15.3%和4.5%。
- 正常睾酮组前列腺癌和临床显著前列腺癌的患病率分别为17.0%和5.1%。
核心结论
- 在既往活检阴性的男性中,总PSA、游离PSA比值和PSA密度对低睾酮与正常睾酮男性的前列腺癌筛查具有相似的诊断特征。
研究设计与样本
- 回顾性分析REDUCE研究安慰剂组中3295例既往活检阴性后2年内接受前列腺活检的男性,按睾酮水平<或≥300 ng/dL分为两组。
主要发现
- 低睾酮组603例(18.3%),前列腺癌92例(15.3%),临床显著前列腺癌27例(4.5%)。
- 正常睾酮组前列腺癌458例(17.0%),临床显著前列腺癌138例(5.1%)。
- 总PSA、游离PSA比值和PSA密度在低睾酮与正常睾酮男性中预测前列腺癌和临床显著前列腺癌的敏感性、特异性和准确性相似。
关键数值与推荐
- 低睾酮定义为睾酮水平<300 ng/dL。
- 临床显著前列腺癌定义为Gleason评分≥7。
临床怎么用
- 对于低睾酮且既往活检阴性的男性,可使用总PSA、游离PSA比值和PSA密度进行前列腺癌筛查,其诊断性能与正常睾酮男性相当。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To evaluate whether total serum PSA, free-PSA ratio and PSA density have similar diagnostic properties for detecting prostate cancer (PCa) and clinically-significant (cs) PCa in men with normal testosterone compared to men with low testosterone with a prior negative biopsy. METHODS: We conducted a retrospective analysis of 3295 men undergoing a 2-year prostate biopsy following a negative prestudy biopsy in the placebo arm of the Reduction by Dutasteride of PCa Events (REDUCE) study. Men were divided in 2 groups based on testosterone level < or ≥300 ng/dL. Diagnostic properties of total serum PSA, free-PSA ratio, and PSA density to predict PCa and csPCa, defined as Gleason score ≥7, were determined for several thresholds and plotted as receiver operator characteristic curves. RESULTS: A total of 603 men (18.3%) had low testosterone. The prevalence of PCa and csPCa was 92 (15.3%) and 27 (4.5%), respectively, for low testosterone men compared to 458 (17.0%) and 138 (5.1%), correspondingly, for normal testosterone men. Total PSA, free-PSA ratio and PSA density showed similar sensitivity, specificity, and accuracy to predict PCa and csPCa among low testosterone men compared to normal testosterone men. CONCLUSION: Among subjects in a clinical trial with a prior negative biopsy, total PSA, free-PSA ratio and PSA density have comparable diagnostic characteristics for PCa screening in low and normal testosterone men.
引用
- Schwarzman LS, Pagani RL, Ohlander SJ, et al. Diagnostic Properties of Total and Free Prostate-Specific Antigen to Predict Overall and Clinically Significant Prostate Cancer Among Men With Low Testosterone and Prior Negative Biopsy. Urology. 2019. PMID: 31733275. doi:10.1016/j.urology.2019.11.004
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。